| Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer J Ledermann, P Harter, C Gourley, M Friedlander, I Vergote, G Rustin, ... New England Journal of Medicine 366 (15), 1382-1392, 2012 | 2233 | 2012 |
| Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised … J Ledermann, P Harter, C Gourley, M Friedlander, I Vergote, G Rustin, ... The lancet oncology 15 (8), 852-861, 2014 | 1793 | 2014 |
| Identification and characterization of ovarian cancer-initiating cells from primary human tumors S Zhang, C Balch, MW Chan, HC Lai, D Matei, JM Schilder, PS Yan, ... Cancer research 68 (11), 4311-4320, 2008 | 1697 | 2008 |
| Periostin Secreted by Epithelial Ovarian Carcinoma Is a Ligand for αVβ3 and αVβ5 Integrins and Promotes Cell Motility L Gillan, D Matei, DA Fishman, CS Gerbin, BY Karlan, DD Chang Cancer research 62 (18), 5358-5364, 2002 | 722 | 2002 |
| Ovarian cancer, version 2.2020, NCCN clinical practice guidelines in oncology DK Armstrong, RD Alvarez, JN Bakkum-Gamez, L Barroilhet, K Behbakht, ... Journal of the National Comprehensive Cancer Network 19 (2), 191-226, 2021 | 611 | 2021 |
| Lipid desaturation is a metabolic marker and therapeutic target of ovarian cancer stem cells J Li, S Condello, J Thomes-Pepin, X Ma, Y Xia, TD Hurley, D Matei, ... Cell stem cell 20 (3), 303-314. e5, 2017 | 556 | 2017 |
| Niraparib monotherapy for late-line treatment of ovarian cancer (QUADRA): a multicentre, open-label, single-arm, phase 2 trial KN Moore, AA Secord, MA Geller, DS Miller, N Cloven, GF Fleming, ... The Lancet Oncology 20 (5), 636-648, 2019 | 515 | 2019 |
| Overall survival in patients with platinum-sensitive recurrent serous ovarian cancer receiving olaparib maintenance monotherapy: an updated analysis from a randomised, placebo … JA Ledermann, P Harter, C Gourley, M Friedlander, I Vergote, G Rustin, ... The lancet oncology 17 (11), 1579-1589, 2016 | 506 | 2016 |
| Targeting cancer stemness in the clinic: from hype to hope C Saygin, D Matei, R Majeti, O Reizes, JD Lathia Cell stem cell 24 (1), 25-40, 2019 | 480 | 2019 |
| Epigenetic resensitization to platinum in ovarian cancer D Matei, F Fang, C Shen, J Schilder, A Arnold, Y Zeng, WA Berry, ... Cancer research 72 (9), 2197-2205, 2012 | 440 | 2012 |
| Adjuvant chemotherapy plus radiation for locally advanced endometrial cancer D Matei, V Filiaci, ME Randall, D Mutch, MM Steinhoff, PA DiSilvestro, ... New England Journal of Medicine 380 (24), 2317-2326, 2019 | 436 | 2019 |
| Clinical activity of pertuzumab (rhuMAb 2C4), a HER dimerization inhibitor, in advanced ovarian cancer: potential predictive relationship with tumor HER2 activation status MS Gordon, D Matei, C Aghajanian, UA Matulonis, M Brewer, GF Fleming, ... Journal of Clinical Oncology 24 (26), 4324-4332, 2006 | 307 | 2006 |
| NF-κB-HOTAIR axis links DNA damage response, chemoresistance and cellular senescence in ovarian cancer AR Özeş, DF Miller, ON Özeş, F Fang, Y Liu, D Matei, T Huang, ... Oncogene 35 (41), 5350-5361, 2016 | 282 | 2016 |
| Tissue transglutaminase links TGF-β, epithelial to mesenchymal transition and a stem cell phenotype in ovarian cancer L Cao, M Shao, J Schilder, T Guise, KS Mohammad, D Matei Oncogene 31 (20), 2521-2534, 2012 | 265 | 2012 |
| NCCN guidelines insights: Ovarian cancer, version 1.2019: Featured updates to the NCCN guidelines DK Armstrong, RD Alvarez, JN Bakkum-Gamez, L Barroilhet, K Behbakht, ... Journal of the National Comprehensive Cancer Network 17 (8), 896-909, 2019 | 262 | 2019 |
| Pembrolizumab in patients with programmed death ligand 1–positive advanced ovarian cancer: Analysis of KEYNOTE-028 A Varga, S Piha-Paul, PA Ott, JM Mehnert, D Berton-Rigaud, A Morosky, ... Gynecologic oncology 152 (2), 243-250, 2019 | 256 | 2019 |
| NCCN guidelines® insights: Ovarian cancer, version 3.2022: Featured updates to the NCCN guidelines DK Armstrong, RD Alvarez, FJ Backes, JN Bakkum-Gamez, L Barroilhet, ... Journal of the National Comprehensive Cancer Network 20 (9), 972-980, 2022 | 242 | 2022 |
| Epithelial ovarian cancer experimental models E Lengyel, JE Burdette, HA Kenny, D Matei, J Pilrose, P Haluska, ... Oncogene 33 (28), 3619-3633, 2014 | 242 | 2014 |
| In vivo tumor growth of high-grade serous ovarian cancer cell lines AK Mitra, DA Davis, S Tomar, L Roy, H Gurler, J Xie, DD Lantvit, ... Gynecologic oncology 138 (2), 372-377, 2015 | 216 | 2015 |
| N-linked glycan structures and their expressions change in the blood sera of ovarian cancer patients WR Alley Jr, JA Vasseur, JA Goetz, M Svoboda, BF Mann, DE Matei, ... Journal of proteome research 11 (4), 2282-2300, 2012 | 216 | 2012 |
